[go: up one dir, main page]

JP2010540444A - 遺伝子産物の濃縮または活性を調節するためのレスベラトロールを含む組成物 - Google Patents

遺伝子産物の濃縮または活性を調節するためのレスベラトロールを含む組成物 Download PDF

Info

Publication number
JP2010540444A
JP2010540444A JP2010525922A JP2010525922A JP2010540444A JP 2010540444 A JP2010540444 A JP 2010540444A JP 2010525922 A JP2010525922 A JP 2010525922A JP 2010525922 A JP2010525922 A JP 2010525922A JP 2010540444 A JP2010540444 A JP 2010540444A
Authority
JP
Japan
Prior art keywords
resveratrol
composition
gene
vitamin
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010525922A
Other languages
English (en)
Japanese (ja)
Inventor
ウィリアム エフ． サーディ，
Original Assignee
レスベラトロル パートナーズ， エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by レスベラトロル パートナーズ， エルエルシー filed Critical レスベラトロル パートナーズ， エルエルシー
Publication of JP2010540444A publication Critical patent/JP2010540444A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2010525922A 2007-09-20 2008-09-17 遺伝子産物の濃縮または活性を調節するためのレスベラトロールを含む組成物 Pending JP2010540444A (ja)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US97381707P 2007-09-20 2007-09-20
US2322708P 2008-01-24 2008-01-24
US2323408P 2008-01-24 2008-01-24
US2323008P 2008-01-24 2008-01-24
US4876908P 2008-04-29 2008-04-29
US4874708P 2008-04-29 2008-04-29
US4875608P 2008-04-29 2008-04-29
PCT/US2008/076707 WO2009039195A1 (fr) 2007-09-20 2008-09-17 Compositions contenant du resvératrol destinées à moduler la concentration ou l'activité d'un produit génique

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013272200A Division JP2014058574A (ja) 2007-09-20 2013-12-27 遺伝子産物の濃縮または活性を調節するためのレスベラトロールを含む組成物

Publications (1)

Publication Number Publication Date
JP2010540444A true JP2010540444A (ja) 2010-12-24

Family

ID=40468316

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010525922A Pending JP2010540444A (ja) 2007-09-20 2008-09-17 遺伝子産物の濃縮または活性を調節するためのレスベラトロールを含む組成物
JP2013272200A Pending JP2014058574A (ja) 2007-09-20 2013-12-27 遺伝子産物の濃縮または活性を調節するためのレスベラトロールを含む組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013272200A Pending JP2014058574A (ja) 2007-09-20 2013-12-27 遺伝子産物の濃縮または活性を調節するためのレスベラトロールを含む組成物

Country Status (4)

Country Link
EP (1) EP2197434A4 (fr)
JP (2) JP2010540444A (fr)
CA (1) CA2699908C (fr)
WO (1) WO2009039195A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013112636A (ja) * 2011-11-28 2013-06-10 Apion Japan Kk サーチュイン１（ｓｉｒｔ１）遺伝子活性化剤及びテロメラーゼ逆転写酵素（ｔｅｒｔ）遺伝子活性化剤
JP2013529685A (ja) * 2010-06-28 2013-07-22 レスベラトロル パートナーズ， エルエルシー レスベラトール含有組成物および使用方法
JP2014185170A (ja) * 2014-06-18 2014-10-02 Apion Japan Kk サーチュイン１（ｓｉｒｔ１）遺伝子活性化剤及びテロメラーゼ逆転写酵素（ｔｅｒｔ）遺伝子活性化剤
JP2015529335A (ja) * 2012-09-12 2015-10-05 バーグ エルエルシー 心臓毒性剤の同定におけるマーカーの使用

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8263051B2 (en) * 2007-08-09 2012-09-11 Hallstar Innovations Corp. Photostabilization of resveratrol with alkoxycrylene compounds
JP5979810B2 (ja) * 2009-10-09 2016-08-31 株式会社山田養蜂場本社 抗老化剤
CA2792993A1 (fr) * 2010-01-21 2011-07-28 Inserm (Institut National De La Sante Et De La Recherche Medicale) Composition particuliere pour son application comme medicament
WO2013074948A1 (fr) 2011-11-16 2013-05-23 Resveratrol Partners, Llc Compositions contenant du resvératrol et des nucléotides
CN102908338B (zh) * 2012-11-20 2014-05-14 晨光生物科技集团天津有限公司 白藜芦醇微胶囊的制备方法
US9138453B2 (en) 2013-10-14 2015-09-22 Biomarker Pharmaceuticals, Inc. Nutrient combinations for affecting an aging process
WO2016102985A1 (fr) * 2014-12-23 2016-06-30 Barokes Pty Ltd. Contenant pour un produit de consommation, revêtu d'une couche contenant du resvératrol
US10702571B2 (en) 2015-12-03 2020-07-07 The University Of North Carolina At Pembroke Materials for cathepsin B enhancement and methods of use
JP6272946B2 (ja) * 2016-05-20 2018-01-31 株式会社山田養蜂場本社 抗老化剤
KR102619197B1 (ko) 2017-01-23 2024-01-03 리제너론 파마슈티칼스 인코포레이티드 Hsd17b13 변종 및 이것의 용도
EP3610029A1 (fr) 2017-04-11 2020-02-19 Regeneron Pharmaceuticals, Inc. Dosage de criblage de l'activité des modulateurs de membres de la famille des hydroxystéroïde (17-bêta) déshydrogénase (hsd17b)
IL319615A (en) 2017-10-11 2025-05-01 Regeneron Pharma HSD17B13 inhibition in the treatment of liver disease in patients expressing the I148M variant of PNPLA3
JP6411624B2 (ja) * 2017-12-26 2018-10-24 株式会社山田養蜂場本社 抗老化剤
JP7507093B2 (ja) 2018-03-21 2024-06-27 リジェネロン・ファーマシューティカルズ・インコーポレイテッド １７β－水酸化ステロイド脱水素酵素１３型（ＨＳＤ１７Ｂ１３）ｉＲＮＡ組成物およびその使用方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005099761A1 (fr) * 2004-04-07 2005-10-27 Resveratrol Partners, Llc Supplement dietetique et procede de traitement de ce dernier
JP2006298876A (ja) * 2005-04-25 2006-11-02 Saisentan Igaku Kenkyusho:Kk サーチュインの活性化剤を含む各種眼疾患治療用組成物
JP2006528950A (ja) * 2003-05-27 2006-12-28 ディーエスエム アイピー アセッツ ビー．ブイ． 新規栄養補助食品組成物及びその使用
WO2007103960A1 (fr) * 2006-03-08 2007-09-13 Allergan, Inc. Traitement oculaire a base d'agents activateurs de la sirtuine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007530417A (ja) * 2003-07-01 2007-11-01 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 細胞及び生物の寿命及びストレス応答を操作するための組成物
US20050158376A1 (en) * 2003-10-23 2005-07-21 Sardi William F. Dietary supplement and method of processing same
US20070149466A1 (en) * 2005-07-07 2007-06-28 Michael Milburn Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
WO2007019416A1 (fr) * 2005-08-04 2007-02-15 Sirtris Pharmaceuticals, Inc. Dérivés de benzimidazole en tant que modulateur du sirtuin

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006528950A (ja) * 2003-05-27 2006-12-28 ディーエスエム アイピー アセッツ ビー．ブイ． 新規栄養補助食品組成物及びその使用
WO2005099761A1 (fr) * 2004-04-07 2005-10-27 Resveratrol Partners, Llc Supplement dietetique et procede de traitement de ce dernier
JP2006298876A (ja) * 2005-04-25 2006-11-02 Saisentan Igaku Kenkyusho:Kk サーチュインの活性化剤を含む各種眼疾患治療用組成物
WO2007103960A1 (fr) * 2006-03-08 2007-09-13 Allergan, Inc. Traitement oculaire a base d'agents activateurs de la sirtuine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN5008009668; ＧＥＳＣＨＥＲ　ＡＮＤＲＥＡＳ　Ｊ: ＣＡＮＣＥＲ　ＥＰＩＤＥＭＩＯＬＯＧＹ　ＢＩＯＭＡＲＫＥＲＳ　＆　ＰＲＥＶＥＮＴＩＯＮ Ｖ１２　Ｎ１０, 200310, Ｐ９５３-９５７ *
JPN6013043157; Ｍｉｎｔｅｌ　Ｐｏｒｔａｌ　｜　Ｓｅａｒｃｈ　［ｏｎｌｉｎｅ］ ［平成２５年８月２６日検索］, 2004 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013529685A (ja) * 2010-06-28 2013-07-22 レスベラトロル パートナーズ， エルエルシー レスベラトール含有組成物および使用方法
JP2013112636A (ja) * 2011-11-28 2013-06-10 Apion Japan Kk サーチュイン１（ｓｉｒｔ１）遺伝子活性化剤及びテロメラーゼ逆転写酵素（ｔｅｒｔ）遺伝子活性化剤
JP2015529335A (ja) * 2012-09-12 2015-10-05 バーグ エルエルシー 心臓毒性剤の同定におけるマーカーの使用
JP2014185170A (ja) * 2014-06-18 2014-10-02 Apion Japan Kk サーチュイン１（ｓｉｒｔ１）遺伝子活性化剤及びテロメラーゼ逆転写酵素（ｔｅｒｔ）遺伝子活性化剤

Also Published As

Publication number Publication date
JP2014058574A (ja) 2014-04-03
CA2699908C (fr) 2012-09-11
EP2197434A4 (fr) 2011-08-10
CA2699908A1 (fr) 2009-03-26
EP2197434A1 (fr) 2010-06-23
WO2009039195A1 (fr) 2009-03-26

Similar Documents

Publication Publication Date Title
JP2010540444A (ja) 遺伝子産物の濃縮または活性を調節するためのレスベラトロールを含む組成物
KR20130048768A (ko) 레스베라트롤을 함유한 조성물과 그 사용방법.
US10016450B2 (en) Anti-glycation methods and compositions
Ke et al. Antioxidant acitivity in vitro and in vivo of the capsule polysaccharides from Streptococcus equi subsp. zooepidemicus
US9226937B2 (en) Compositions containing resveratrol and nucleotides
US20100004344A1 (en) Anti-oxidant dietary composition containing fruits and vegetables, method for preparing the same and use of the composition
US20160278417A1 (en) Nutritionally Enhanced Fraction From Rice Bran And Method of Lowering Insulin Resistance Using Same
Lila Impact of bioflavonoids from berryfruits on biomarkers of metabolic syndrome
Oyegoke et al. Role of dietary fibre and phytonutrients in human health and nutrition
US11173187B2 (en) Concentrated oil-based polyphenol composition and a method of producing the oil-based polyphenol composition
Mizuno et al. Blueberries and metabolic syndrome
CN115645431B (zh) 一种组合物及其应用
Ji et al. Dietary wolfberry and retinal degeneration
JP5591122B2 (ja) カシューアップルのプロアントシアニジン、プロアントシアニジン含有組成物、およびその用途
Sharma et al. Compounds and Their Extracts on Metabolic
Liao et al. Novel Biological Synthesis of Nutrients for Chronic Diseases Intervention
Lu et al. Evaluation of synergistic antioxidant interactions of lutein and cyanidin-3-O-glucoside and their roles in age-related macular degeneration
Seeram Strawberry phytochemicals and human health: a review
CN115590874A (zh) 锦葵素-3-o-葡萄糖苷在制备药物或保健食品的应用
Suwannapong Antidiabetic and antioxidant activities of fruit pulp extracts
Nurdin Effect of Antioxidant-dietary Fiber Mixtures on Cancer Growth in Colorectal Cancer-induced Rats
Farris Resveratrol and Synthetic Sirtuin Activators
US20110287145A1 (en) Nutrition composition containing omega-3 fatty acids and mcts
Xian Wen Extraction and analysis of antioxidant capacity in rice bran extracts from different Sarawak local rice varieties
Ames Delaying (or Accelerating) the Degenerative Diseases of Aging

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110428

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120921

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121221

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130829